← Back to Search

Other

BI 764524 for Diabetic Retinopathy (HORNBILL Trial)

Phase 1 & 2

Waitlist Available

Research Sponsored by Boehringer Ingelheim

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 22 weeks

Awards & highlights

HORNBILL Trial Summary

This trial is investigating the safety and effectiveness of a new medication for people with diabetic retinopathy with diabetic macular ischemia.

Eligible Conditions

Diabetic Retinopathy

HORNBILL Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 22 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~22 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 22 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Multiple dosing (MD) part: Number of patients with drug related adverse events (AEs) from drug administration till end of study (EOS)

Single rising dose (SRD) part: Number of participants with dose limiting events

Secondary outcome measures

MD part: Change from baseline of BCVA at Visit 4

MD part: Change from baseline of BCVA at Visit 5

MD part: Change from baseline of BCVA at Visit 6

+12 more

HORNBILL Trial Design

3Treatment groups

Experimental Treatment

Placebo Group

Group I: SRD part: BI 764524Experimental Treatment1 Intervention

SRD part: BI 764524

Group II: MRD part: BI 764524Experimental Treatment1 Intervention

MRD part: BI 764524

Group III: MRD part: Sham control of BI 764524Placebo Group1 Intervention

MRD part: Sham control of BI 764524

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

BI 764524

2020

Completed Phase 2

~50

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Boehringer IngelheimLead Sponsor

2,505 Previous Clinical Trials

11,340,247 Total Patients Enrolled

4 Trials studying Diabetic Retinopathy

360 Patients Enrolled for Diabetic Retinopathy

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many health care centers are conducting research involving this program in Canada?

"Emerson Clinical Research Institute in Falls Church, Austin Research Center for Retina, PLLC in Austin and the Retina Research Institute of Texas are amongst 4 accessible trial locations."

Answered by AI

Is this trial recruiting participants at the moment?

"The data hosted on clinicaltrials.gov confirms that this study is currently recruiting patients, with a commencement date of June 12th 2020 and the last edit being dated November 14th 2022."

Answered by AI

What is the aggregate amount of participants in this research?

"To fully launch this clinical trial, 48 individuals that pass the pre-determined criteria must be recruited. Emerson Clinical Research Institute in Falls Church, Virginia and Austin Research Center for Retina, PLLC in Austin, Texas are two of many potential sites where patients can join the study."

Answered by AI